# Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

> **NCT03591744** · PHASE1 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Plasma Cell Leukemia

## Interventions

- **DRUG:** Bortezomib
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **DRUG:** Pegylated Liposomal Doxorubicin Hydrochloride

## Key facts

- **NCT ID:** NCT03591744
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-25
- **Primary completion:** 2019-10-25
- **Final completion:** 2019-10-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Budgetary constraints
- **Last updated:** 2018-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03591744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03591744, "Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03591744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*